Cervical Ripening Drugs Market


Market Outline: 

Cervical ripening is defined as the softening of cervix prior to onset of labor contractions and it is necessary for the cervical dilation and passage of fetus. Cervix softens, thins, dilates, and relaxes in response to the uterine contractions and allows the cervix to easily pass over the fetal part during labor. Cervical ripening drugs are used before the induction of labor for the dilatation of cervix. Cervical ripening drugs market is associated with the reduced collagen fiber strength, decrease in collagen fiber alignment, and diminished the tensile strength of extracellular cervical matrix. The common techniques used for the cervical ripening are mechanical interventions such as insertion of cervical catheters and dilators and application of cervical ripening agents such as prostaglandins.


Market Dynamics: 

Growing usage of cervical ripening drugs before the induction of labor, rise in R&D activities for the innovation of newer drugs, increase in awareness about cervical ripening drugs in developed and developing countries, low cost of drugs, and government initiations for improving the baby deliveries are anticipated to fuel the cervical ripening drugs market over the forecast period. However, stringent regulatory policies for product approval, adverse effects associated with the cervical ripening drugs, and alternative procedures for the childbirth are expected to hinder the growth of surgical ripening drugs market over the forecast period.


Market Scope: 

Cervical ripening drugs market is segmented on the basis of drug type, route of administration, distribution channel, and region

Based on the drug type, market is segmented into the following:

  • Prostaglandins
  • Oxytocin
  • Progesterone Receptor Antagonists
  • Relaxin
  • Estrogen
  • Others

Based on the route of administration, market is segmented into the following:

  • Oral
  • Intravenous
  • Vaginal

Based on the distribution channel, market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others



 North America

  • US
  • Canada


  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe


  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America

Middle East and Africa (MEA)

  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa

Rest of MEA


Market Summary: 

Cervical ripening drugs market is projected to grow at a significant rate with increase in the usage of cervical ripening drugs prior to the induction of labor. Moreover, acquisitions and mergers, product approvals, and product launchings are the key strategies adopted by market players to generate increased revenue in the market. For instance, in February 2012, Ferring Pharmaceuticals acquired Cytokine PharmaSciences Inc. and the acquisition includes manufacturing assets of Cervidil (Dinoprostone) in U.S. and Canada.


Regional Analysis:  

Geographically, global cervical ripening drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America cervical ripening drugs market growth driven by increase in the R&D for the innovation of newer drugs and high awareness about the cervical ripening drugs among the physicians. Europe cervical ripening drugs market has a lucrative growth owing to high adoption of cervical ripening drugs, launching of newer drugs by the market players. Asia Pacific cervical ripening drugs market has significant share owing to rise in number of female population, government initiations for the baby birth, and increase in the using of cervical ripening drugs before the induction of labor are propel the market. Middle East and Africa market has a prominent share owing to increase in the number of births and rise in awareness about the cervical ripening drugs are in the region.


Competition Assessment: 

Some of the players in the global market include:

  • Ferring B.V. (Switzerland)
  • Azanta A/S (Denmark)
  • Novartis AG (Switzerland)
  • GlaxoSmithKline plc (U.K.)
  • AstraZeneca plc (U.K.)
  • Pfizer, Inc. (U.S.)
  • Bayer AG (Germany)


Notable Market Developments: 

  • In February 2016, Azanta A/S filed marketing authorization application in Nordic countries for Angusta (Misoprostol), which is indicated in induction of labor


Key Features of the Report:

  • The report provides granular level information about the market size, regional market share, historic market (2015 to 2019) and forecast (2020 to 2026)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market



PBI Location Map


Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084


Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX